Skip to main content

LumiraDx Limited (LMDX)

LumiraDx will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Market Capn/a
Revenue (ttm)24.94M
Net Income (ttm)n/a
Shares Outn/a
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Ex-Dividend Daten/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Price Targetn/a
Est. Earnings Daten/a

About LMDX

LumiraDx is a next-generation point of care, or POC, diagnostic company. We have developed and launched our LumiraDx Platform, or Platform, which is an integrated system comprised of a small, versatile POC instrument, or Instrument, precise, low-cost microfluidic test strips, and seamless, secure digital connectivity. We currently have four tests available on our Platform and a broad menu of tests in development. Our proprietary Platform is designed to simplify, scale down, and integrate multiple testing methodologies onto a single instrument a...

IndustryPharmaceutical Preparations
IPO DatePending
CEORon Zwanziger
Stock ExchangeNASDAQ
Ticker SymbolLMDX
Full Company Profile


COVID-19 test maker LumiraDx files for a $100 million US IPO

LumiraDx, a UK-based provider of point-of-care diagnostics including COVID-19 tests, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

8 months ago - NASDAQ

LumiraDx IPO Registration Document (S-1)

LumiraDx Limited has filed to go public with an IPO on the NASDAQ.

8 months ago - SEC

Hospital emergency departments to use rapid Covid-19 testing with results in 12 minutes

A new rapid test for Covid-19 can return results in just 12 minutes, Health Minister Robin Swann has said.

8 months ago - The Irish News

LumiraDx Receives Authorization by Switzerlandu00b4s Federal Office of Public Health Showing Excellent Positive Agree...

LumiraDx, the next generation point-of-care diagnostic company, announced today that it has received Switzerland Federal Office of Public...

8 months ago - PRNewswire